The Humanitarian Device Exemption (HDE) is an FDA regulatory pathway designed for devices that address rare conditions where conducting large clinical trials is impractical due to the small patient population. An HDE-approved device is called a Humanitarian Use Device (HUD). The key distinction from PMA is that HDE requires evidence of safety and "probable benefit" rather than full proof of effectiveness — a lower evidentiary bar reflecting the difficulty of conducting adequately powered studies in rare disease populations.

Eligibility

To qualify for HDE, a device must:

  • Be intended to treat or diagnose a condition affecting fewer than 8,000 individuals per year in the United States
  • Have no comparable approved device available
  • Demonstrate that the probable benefit outweighs the risks

Relevance to BCI

The HDE pathway is potentially relevant to BCI devices targeting rare conditions:

  • ALS: Approximately 5,000 new cases per year in the US — potentially qualifying for HDE
  • Locked-in syndrome: Very rare, likely qualifying for HDE
  • Brainstem stroke: Rare subset of stroke patients who might benefit from BCI

However, the BCI field faces a strategic tension: HDE approval limits the market (only the specified rare condition), while PMA approval for a broader indication (e.g., "tetraplegia of any cause") opens a larger market but requires more extensive clinical data. Companies must weigh faster approval via HDE against the commercial limitations of a narrow indication.

Comparison with PMA

| Feature | HDE | PMA | |---------|-----|-----| | Patient population | <8,000/year | Any size | | Evidence standard | Safety + probable benefit | Safety + effectiveness | | Clinical trial size | Small, often single-arm | Large, often randomized | | Time to approval | Generally faster | Longer | | Commercial scope | Limited to HUD indication | Full commercial marketing | | IRB approval required for each use | Yes | No |

Institutional Review Board Requirement

A unique aspect of HDE is that each institution where the device is used must have Institutional Review Board (IRB) approval for its use — an additional administrative requirement that does not apply to PMA-approved devices. This can limit practical adoption even after HDE approval.